Chinese Association for Biomaterials 


A “Subcutaneous Pancreas"

14 Feb 2020 8:00 AM | Anonymous

Cell replacement therapy such as intrahepatic transplantation of donor islets is relatively successful for type 1 diabetes in some patients. However, there are a number of limitations including immediate blood-mediated inflammatory response, potential risks of thrombosis and localized steatosis, and inability to retrieve or replace failed cells. Subcutaneous site is less invasive and easier-to-access but lacks sufficient vasculature to support the islet function. Dr. Minglin Ma and his collaborators reported a pre-vascularized islet construct that functioned in the subcutaneous site and corrected diabetes in mice for 3 months. (

CAB is a non-profit organization.

Powered by Wild Apricot Membership Software